Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronate duration trial in newly treated multiple myeloma
NL-OMON26780Phase 3Active, not recruiting
- Sponsor
- HOVON
- Start
- Apr 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of zoledronate in multiple myeloma (MM) (2 arms), sponsored by HOVON. Primary endpoint: Time to first skeletal-related event from randomization. Started Apr 2004; status: active, not recruiting.
02
Drugs
zoledronate
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON26780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON26780.